Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

The Urinary Exosomal miRNA Expression Profile is Predictive of Clinical Response in Lupus Nephritis.

Garcia-Vives E, Solé C, Moliné T, Vidal M, Agraz I, Ordi-Ros J, Cortés-Hernández J.

Int J Mol Sci. 2020 Feb 18;21(4). pii: E1372. doi: 10.3390/ijms21041372.

2.

Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience.

Segarra A, Arredondo KV, Jaramillo J, Jatem E, Salcedo MT, Agraz I, Ramos N, Carnicer C, Valtierra N, Ostos E.

Lupus. 2020 Feb;29(2):118-125. doi: 10.1177/0961203319896018. Epub 2019 Dec 22.

PMID:
31865857
3.

The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes.

García-Carro C, Vergara A, Agraz I, Jacobs-Cachá C, Espinel E, Seron D, Soler MJ.

J Clin Med. 2019 Jun 17;8(6). pii: E864. doi: 10.3390/jcm8060864. Review.

4.

Prevalence and Risk Factors for Major Infections in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis: Influence on the Disease Outcome.

Garcia-Vives E, Segarra-Medrano A, Martinez-Valle F, Agraz I, Solans-Laque R.

J Rheumatol. 2020 Mar;47(3):407-414. doi: 10.3899/jrheum.190065. Epub 2019 Jun 15.

PMID:
31203229
5.

Antibodies to M-type phospholipase A2 receptor (PLA2R) in membranous lupus nephritis.

Garcia-Vives E, Solé C, Moliné T, Alvarez-Rios AM, Vidal M, Agraz I, Ordi-Ros J, Cortés-Hernández J.

Lupus. 2019 Mar;28(3):396-405. doi: 10.1177/0961203319828521. Epub 2019 Feb 13.

PMID:
30760090
6.

Anti-phospholipase A2 receptor antibody and spontaneous remission in membranous nephropathy.

Diaz M, Agraz I, Soler MJ.

Clin Kidney J. 2019 Feb;12(1):33-35. doi: 10.1093/ckj/sfy079. Epub 2018 Oct 3.

7.

Mesangial C4d Deposits in Early IgA Nephropathy.

Segarra A, Romero K, Agraz I, Ramos N, Madrid A, Carnicer C, Jatem E, Vilalta R, Lara LE, Ostos E, Valtierra N, Jaramillo J, Arredondo KV, Ariceta G, Martinez C.

Clin J Am Soc Nephrol. 2018 Feb 7;13(2):258-264. doi: 10.2215/CJN.02530317. Epub 2017 Nov 16.

8.

Renal Biopsy in Type 2 Diabetic Patients.

Espinel E, Agraz I, Ibernon M, Ramos N, Fort J, Serón D.

J Clin Med. 2015 May 18;4(5):998-1009. doi: 10.3390/jcm4050998. Review.

9.

Predictors of response and relapse in patients with idiopathic membranous nephropathy treated with tacrolimus.

Caro J, Gutiérrez-Solís E, Rojas-Rivera J, Agraz I, Ramos N, Rabasco C, Espinosa M, Valera A, Martín M, Frutos MÁ, Perea L, Juárez GF, Ocaña J, Arroyo D, Goicoechea M, Fernández L, Oliet A, Hernández Y, Romera A, Segarra A, Praga M; Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN).

Nephrol Dial Transplant. 2015 Mar;30(3):467-74. doi: 10.1093/ndt/gfu306. Epub 2014 Oct 1.

PMID:
25274748
10.

[Diagnostic value of soluble urokinase-type plasminogen activator receptor serum levels in adults with idiopathic nephrotic syndrome].

Segarra A, Jatem E, Quiles MT, Arbós MA, Ostos H, Valtierra N, Carnicer C, Agraz I, Salcedo MT.

Nefrologia. 2014;34(1):46-52. doi: 10.3265/Nefrologia.pre2013.Oct.12256. Spanish.

11.

Grover's disease in a peritoneal dialysis patient.

Jatem E, Agraz I, Semidei ME, Ferrer B, Ramos R, Fort J.

Nefrologia. 2013;33(4):608-9. doi: 10.3265/Nefrologia.pre2013.May.11220. English, Spanish. No abstract available.

12.

[IgA nephropathy with crescentic glomerulonephritis and ANCA positive].

Ara J, Bonet J, Rodríguez R, Mirapeix E, Agraz I, Romero R.

Nefrologia. 2005;25(6):712-7. Spanish.

13.

[Histoplasmosis in a renal transplant patient].

Ara J, Matas L, Lauzurica R, Agraz I, Bayes B, Bonet J, Romero A, Pérez R.

Nefrologia. 2005;25(6):706-11. Spanish.

14.

[Analysis of heart rate as a risk factor associated with the progression of chronic renal failure].

Mora-Maciá J, Cases A, Alami M, Agraz I, Barceló P, Esqué J.

Med Clin (Barc). 2002 Sep 7;119(7):245-8. Spanish.

PMID:
12236983
15.

Are there differences in renal posttransplant evolution between the first and the second recipient from the same donor?

Guirado LL, Herreros MA, Díaz M, Durán F, Díaz JM, Facundo C, Agraz I, Solà R.

Transplant Proc. 2002 Feb;34(1):347-8. No abstract available.

PMID:
11959318
16.

Use of cytomegalovirus antigenemia as a marker for preemptive treatment.

Guirado L, Herreros MA, Muñoz JM, Rabella N, Facundo C, Agraz I, Díaz M, Diaz JM, Durán F, Solà R.

Transplant Proc. 2002 Feb;34(1):67-8. No abstract available.

PMID:
11959188
17.

Acyclovir prophylaxis of cytomegalovirus disease in kidney transplant recipients.

Vila A, Guirado LL, Balius A, Díaz M, Baró E, Olaya M, Andrade M, Agraz I, Solá R.

Transplant Proc. 1999 Sep;31(6):2335-6. No abstract available.

PMID:
10500605
18.

Renal transplantation and graft survival and its influencing factors.

Agraz I, Guirado LL, López-Navidad A, Caballero P, Andrade M, Vila A, Solá R.

Transplant Proc. 1999 Sep;31(6):2296-300. No abstract available.

PMID:
10500586
19.

Treatment with mycophenolate mofetil in kidney transplant patients with organs from donors aged over 60 years: one-year monitoring results.

Agraz I, Guirado L, Andrade M, Olaya M, Vila A, Solá R.

Transplant Proc. 1999 Sep;31(6):2272-4. No abstract available.

PMID:
10500573
20.

Interruption of the administration of cyclosporin after renal transplant: long-term results.

Solá R, Guirado LL, Agraz I, Paredes D, Vizcarra D, Rodríguez S.

Nephrol Dial Transplant. 1998 Nov;13(11):2981-2. No abstract available.

PMID:
9829527
21.

Renal transplantation with limit donors: to what should the good results obtained be attributed?

Solá R, Guirado L, López Navidad A, Caballero F, Agraz I, Díaz M, Paredes D, Rodrígez S, Vizcarra D.

Transplantation. 1998 Nov 15;66(9):1159-63.

PMID:
9825811
22.

Elderly donors (60 to 87 years) in renal transplantation: good results after 5 years.

Guirado L, Sola R, Agraz I, Díaz M, Paredes AV, Vizcarra D, Barcelo P.

Transplant Proc. 1998 Aug;30(5):2276. No abstract available.

PMID:
9723469
23.

Treatment of kidney transplants with chronic rejection using angiotensin-converting enzyme inhibitors.

Paredes D, Sola R, Guirado L, Ibeas J, Agraz I, Vizcarra D, Algaba F.

Transplant Proc. 1997 Sep;29(6):2587-8. No abstract available.

PMID:
9290753

Supplemental Content

Support Center